FDA-Approved Obesity Medications: Dosing and Side Effects
Semaglutide 2.4 mg should be prioritized as first-line pharmacotherapy for most patients with obesity, given its superior weight loss efficacy (average 15% total body weight loss) and favorable benefit-risk profile 1.
First-Tier Agents
Semaglutide 2.4 mg (Wegovy)
- Dosing: Start 0.25 mg subcutaneously weekly, titrate monthly: 0.5 mg → 1.0 mg → 1.7 mg → maintenance 2.4 mg weekly 1
- Side Effects:
- Nausea and vomiting (dose-dependent, mitigated by gradual titration)
- Increased risk of pancreatitis and gallbladder disease
- Delayed gastric emptying 1
- Key Advantage: Glucoregulatory benefits; also approved for type 2 diabetes 1
Tirzepatide
- Dosing: Emerging as highly effective with even greater weight loss than semaglutide in phase 3 trials 2, 3, 4
- Side Effects: Similar GI profile to GLP-1 agonists 3
- Note: Represents next-generation dual/triple receptor agonist technology 3
Second-Tier Agents
Liraglutide 3.0 mg (Saxenda)
- Dosing: Start 0.6 mg subcutaneously daily, increase weekly by 0.6 mg to maintenance 3.0 mg daily 1
- Side Effects:
- Nausea and vomiting (requires gradual titration)
- Pancreatitis and gallbladder disease risk
- Delayed gastric emptying 1
- Clinical Context: Glucoregulatory benefits; dual indication for type 2 diabetes 1
Phentermine-Topiramate ER (Qsymia)
- Dosing: Start 3.75/23 mg daily for 14 days, then 7.5/46 mg daily; may increase to 11.25/69 mg or maximum 15/92 mg daily 1
- Side Effects:
- Cardiovascular: Increased heart rate and blood pressure
- Teratogenicity (topiramate) - requires effective contraception in women of childbearing potential
- Cognitive effects (topiramate component) 1
- Monitoring: Blood pressure and heart rate periodically 1
- Contraindications: History of cardiovascular disease, uncontrolled hypertension 1
- Preferred Use: Patients with comorbid migraines 1
Naltrexone-Bupropion ER (Contrave)
- Dosing: Titrate over 4 weeks: Week 1: 8/90 mg daily → Week 2: 8/90 mg twice daily → Week 3: 16/180 mg AM, 8/90 mg PM → Week 4+: 16/180 mg twice daily (maintenance) 1
- Side Effects:
- Seizure risk (bupropion component)
- Increased blood pressure and heart rate
- Psychiatric effects 1
- Monitoring: Blood pressure and heart rate, especially first 12 weeks 1
- Contraindications: Seizure disorders, concurrent opiate use 1
- Preferred Use: Patients attempting smoking cessation or with comorbid depression 1
Not Recommended
Orlistat (Xenical, Alli)
- AGA Position: Suggests against routine use 1
- Dosing: 120 mg three times daily with meals
- Side Effects:
- Significant GI adverse effects (fecal urgency, oily spotting, flatulence)
- Fat-soluble vitamin malabsorption 1
- Required: Daily multivitamin supplementation 1
- Rationale for Non-Recommendation: Minimal weight loss benefit (2.6 kg vs placebo) with substantial GI burden 5
- Exception: May be reasonable for patients who highly value even small weight loss and can tolerate GI effects 1
Phentermine (Monotherapy)
- Status: FDA-approved but only for short-term use (≤12 weeks) 2, 6
- Note: Not recommended for chronic obesity management; included in combination product above 6
Specialized Agent
Setmelanotide
- Indication: Ultra-rare genetic obesity syndromes (e.g., POMC, PCSK1, LEPR deficiency) 4, 6
- Note: Outside scope of general obesity management 1
Critical Implementation Points
All anti-obesity medications must be used chronically, not short-term 1. Weight regain occurs with discontinuation.
Medication selection algorithm:
- Default choice: Semaglutide 2.4 mg (highest efficacy, moderate evidence) 1
- If comorbid migraines: Phentermine-topiramate ER 1
- If attempting smoking cessation or depression: Naltrexone-bupropion ER 1
- If cardiovascular disease or uncontrolled hypertension: Avoid phentermine-topiramate; use GLP-1 agonists 1
- If seizure history: Avoid naltrexone-bupropion 1
- If on chronic opiates: Avoid naltrexone-bupropion 1
- If women of childbearing potential: Avoid phentermine-topiramate unless using reliable contraception 1
Comparative Efficacy Data
At 52 weeks, proportion achieving ≥5% weight loss 5:
- Phentermine-topiramate: 75% (OR 9.22 vs placebo)
- Liraglutide: 63% (OR 5.54 vs placebo)
- Naltrexone-bupropion: 55% (OR 3.96 vs placebo)
- Lorcaserin: 49% (OR 3.10 vs placebo) - Note: withdrawn from market
- Orlistat: 44% (OR 2.70 vs placebo)
- Placebo: 23%
Mean excess weight loss vs placebo 5:
- Phentermine-topiramate: -8.8 kg
- Liraglutide: -5.3 kg
- Naltrexone-bupropion: -5.0 kg
- Orlistat: -2.6 kg
Common Pitfalls
- Discontinuing medications after initial weight loss: Obesity is chronic; medications require indefinite continuation 1
- Inadequate dose titration: GLP-1 agonist GI side effects are minimized by gradual titration 1
- Failing to screen for contraindications: Particularly teratogenicity (phentermine-topiramate), seizure risk (naltrexone-bupropion), and cardiovascular disease (phentermine-topiramate) 1
- Not monitoring vital signs: Blood pressure and heart rate monitoring required for phentermine-containing and naltrexone-bupropion products 1
- Using orlistat as first-line: Minimal efficacy with high GI burden 1, 5